Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMMU $2.20 0.3800 +20.88%
SCLN $8.76 0.6500 +8.01%
VBLT $3.39 0.2300 +7.28%
PVCT $0.52 0.0298 +6.11%
SNSS $0.79 0.0250 +3.29%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

KITE $41.47 -5.7200 -12.12%
OHRP $3.16 -0.3700 -10.48%
PBYI $39.72 -4.2600 -9.69%
CRIS $1.42 -0.1500 -9.55%
ATRA $17.16 -1.6800 -8.92%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | Next > | Last >>

Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab

(Immunocore) Jan 20, 2016 - Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced that it has started a Phase Ib/II combination trial for the treatment of metastatic cutaneous melanoma.
read corporate press release 

Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma

(StreetInsider) Jan 20, 2016 - Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces the initiation of a Phase 3 clinical trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) for the treatment of patients with hepatic dominant ocular melanoma (OM).
read article 

Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancreatic Cancer

(TheStreet) Jan 19, 2016 - Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of gemcitabine-treated historical controls; of the evaluable tumors, 30 percent had partial response and another 30 percent had stable disease.
read article 

New Target Identified For Reducing Cancer Metastasis

(Medical College of Georgia/JAGWIRE) Jan 19, 2016 - A protein that is constantly expressed by cancer cells and quiescent in healthy ones appears to be a solid target for reducing cancer’s ability to spread, scientists report.
read article 

Finding the Needle in a Microbial Haystack: Penn Researchers Test New Pathogen Detection Technology

(Penn Medicine) Jan 15, 2016 - Patients who are undergoing treatment for diseases such as cancer often face the added challenge of a compromised immune system, which can be a toll both of their condition and the drugs used to treat it, leaving them vulnerable to various opportunistic infections.
read press release 

Mysterious Cancers Of 'Unknown' Origin In Men Traced Back To HPV

(Fox News/LiveScience) Jan 19, 2016 - Some cancers are mysterious, in that doctors cannot determine where they originate and how they will spread. These cancers often are given the unwieldy name "unknown primary squamous cell carcinoma" (UPSCC).
read article 

New Findings May Enhance Parp Inhibitors Therapy In Breast Cancer

(MD Anderson) Jan 18, 2016 - Findings from a new study reveal that PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers.
read press release 

ASCO: CRP Predicts Complications After Esophagectomy

(Physician’s Briefing/HealthDay News) Jan 19, 2016 - C-reactive protein (CRP) on postoperative day 4 (POD 4) after esophagectomy is associated with increased odds of serious infectious complications (SICs), according to a study presented at the American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium, held from Jan. 21 to 23 in San Francisco.
read article 

ASCO: VTE Is Risk Factor for Recurrence in Esophageal Cancer

(Physician’s Briefing/HealthDay News) Jan 19, 2016 - For patients with esophageal cancer, venous thromboembolism (VTE) is a risk factor for recurrence, according to a study presented at the American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium, held from Jan. 21 to 23 in San Francisco.
read article 

National Cancer Data Base Study Results Define an Optimal Waiting Time Before Surgery Following Chemoradiotherapy for Rectal Cancer

(American College of Surgeons) Jan 20, 2016 - Researchers analyzing data from the National Cancer Data Base (NCDB) have found that patients who had a cancer operation at precisely eight weeks--56 days--after the end of combined chemoradiotherapy had the best overall survival and successful removal of their residual tumors.
read press release 

Skin Cancer More Deadly When Caught During Pregnancy

(Reuters Health) Jan 20, 2016 - Melanoma, the deadliest form of skin cancer, may be even more dangerous when it’s diagnosed in women during pregnancy or within a year of giving birth, a U.S. study suggests.
read article 

AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

(StreetInsider) Jan 20, 2016 - Marks the second Breakthrough Therapy Designation for venetoclax; an application is currently under review for single agent venetoclax treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including patients with the 17p deletion genetic mutation.
read article 

Updated Data Shows ONIVYDE(R) (irinotecan liposome injection) Combination Regimen Increased One Year Survival by 63% in Patients with Metastatic Pancreatic Cancer

(Yahoo! Finance) Jan 19, 2016 - Results based on an updated analysis from the NAPOLI-1 Phase 3 study in post-gemcitabine pancreatic cancer; additional data to be presented at the ASCO GI 2016 conference indicate observed overall survival and progression free survival benefits for the ONIVYDE combination regimen compared to 5-FU and leucovorin alone were greatest among patients with the highest baseline CA19-9 levels.
read article 

APNewsbreak: Livestrong CEO Resigns After Less Than 1 Year

(ABC News/Associated Press) Jan 19, 2016 - The chief executive and president of the Livestrong cancer foundation, which has struggled with sharp declines in donations and revenue since founder Lance Armstrong's performance-enhancing drug use scandal, resigned Tuesday after less than one year on the job to focus on her family.
read article 

J&J to Cut 3,000 Jobs In Struggling Device Division

(Reuters) Jan 19, 2016 - Johnson & Johnson said on Tuesday it would cut about 3,000 jobs within its medical devices unit over the next two years, or about 4 to 6 percent of the struggling division's global workforce, to generate annual cost savings of up to $1 billion and focus on more innovative products.
read article 

Eli Lilly Seeks FDA Approval for Rheumatoid-Arthritis Drug

(Wall Street Journal) Jan 19, 2016 - Eli Lilly & Co. on Tuesday said it filed a new drug application with the U.S. Food and Drug Administration for an oral rheumatoid-arthritis treatment, and the pharmaceutical company affirmed its earnings guidance for the year.
read article (paid subscription required) 

Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL

(Genmab A/S) Jan 19, 2016 - Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the use of Arzerra® (ofatumumab) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL).
read corporate press release 

Families Happier With Less Aggressive End-Of-Life Cancer Care

(Reuters Health) Jan 19, 2016 - Families may be more satisfied with end-of-life care for loved ones dying of cancer when treatment is focused on comfort rather than aggressive treatment and provided outside of a hospital, a U.S. study suggests.
read article 

Two Indian States Halt Sales Of Roche's Avastin Drug

(Reuters) Jan 19, 2016 - Two Indian states have put sales of Swiss drugmaker Roche's blockbuster drug Avastin on hold, officials said on Tuesday, after it hampered the vision of 15 patients who used it for a condition it is not officially meant to treat.
read article 

Biden Pledges Faster U.S. Approval For Cancer Drug Cocktails

(Reuters) Jan 19, 2016 - U.S. Vice President Joe Biden said on Tuesday that the United States would speed up the approval of promising new drug combinations in his government's newly announced drive to cure cancer "once and for all”.
read article 

Transgenomic Launches New MX-ICP Panels for Liquid Biopsy Detection of RAS and PIK3CA Tumor Mutations

(Morningstar) Jan 19, 2016 - Transgenomic, Inc. today announced the launch of the MX-ICP RAS Analysis and the MX-ICP PIK3CA Analysis, two new cancer panels based on the company’s Multiplexed ICE-COLD PCR™ (MX-ICP) technology.
read article 

IRX Therapeutics and ImmunID Announce Collaboration to Predict Response to IRX-2 Cancer Immunotherapy Using ImmunTraCkeR®

(IRX Therapeutics) Jan 19, 2016 - IRX Therapeutics, a clinical-stage bioresearch company developing cancer immunotherapies, and ImmunID, an immune molecular diagnostics and precision medicine company, today announced they have entered into a collaboration agreement for prediction of response to the IRX-2 immunotherapy candidate using the ImmunTraCkeR® assay.
read corporate press release 

Baxalta Granted EU Marketing Authorization for ONCASPAR (pegaspargase) as a Component of Combination Therapy in Acute Lymphoblastic Leukaemia (ALL)

(TheStreet) Jan 19, 2016 - Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that the European Commission has granted Marketing Authorization for use of ONCASPAR as a combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
read article 

Oncology Group Criticizes Insurers' Cancer Care Guidelines

(Pittsburgh Post-Gazette) Jan 19, 2016 - Doctors at the two leading health care systems in Pittsburgh — Allegheny Health Network and UPMC — use different guidelines to treat people with cancer, but they say their programs are not interfering with care, despite a warning by a professional group that such guidelines too often emphasize cost control over what’s best for the patient.
read article 

Researchers Advocate Improvements In End-Of-Life Care

(Dana-Farber) Jan 19, 2016 - Three Dana-Farber Cancer Institute researchers, writing in a special issue of JAMA published today, make the case for policies and practices that give terminally ill patients more control over how and where they will die.
read press release